Substance Use Disorders (SUD)

The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens

This review (2016) investigates and proposes a model how psychedelics work in the brain, specifically with regards to the 5-HT (serotonin) 2C receptor. The authors also explain how this mechanism may work to treat addiction.

Authors

  • Canal, C. E.
  • Murnane, K. S.

Published

Journal of Psychopharmacology
meta Study

Abstract

Classic hallucinogens share pharmacology as serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptor agonists. Unique among most other Schedule 1 drugs, they are generally non-addictive and can be effective tools in the treatment of addiction. Mechanisms underlying these attributes are largely unknown. However, many preclinical studies show that 5-HT2C agonists counteract the addictive effects of drugs from several classes, suggesting this pharmacological property of classic hallucinogens may be significant. Drawing from a comprehensive analysis of preclinical behavior, neuroanatomy, and neurochemistry studies, this review builds rationale for this hypothesis, and also proposes a testable, neurobiological framework. 5-HT2C agonists work, in part, by modulating dopamine neuron activity in the ventral tegmental area-nucleus accumbens (NAc) reward pathway. We argue that activation of 5-HT2C receptors on NAc shell, GABAergic, medium spiny neurons inhibits potassium Kv1.x channels, thereby enhancing inhibitory activity via intrinsic mechanisms. Together with experiments that show that addictive drugs, such as cocaine, potentiate Kv1.x channels, thereby suppressing NAc shell GABAergic activity, this hypothesis provides a mechanism by which classic hallucinogen-mediated stimulation of 5-HT2C receptors could thwart addiction. It also provides a potential reason for the non-addictive nature of classic hallucinogens.

Available with Blossom Pro

Research Summary of 'The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens'

Introduction

Canal and colleagues review the pharmacology and addiction-related properties of classic hallucinogens (CH), a class that includes tryptamines (for example psilocybin, DMT), ergolines (LSD), and phenylalkylamines (for example mescaline, DOB). They emphasise that CH share high-affinity agonism at serotonin 5-HT2 GPCR subtypes (5-HT2A, 5-HT2B, 5-HT2C) and that blockade of 5-HT2 receptors attenuates many of their psychoactive effects. Despite these shared pharmacological features, CH are generally reported by experienced users and by controlled preclinical studies to have low addiction liability, a contrast to many other Schedule I substances; the mechanistic basis for this apparent non-addictive profile remains uncertain. This paper sets out to synthesise behavioural, neuroanatomical and neurochemical preclinical findings and to propose a testable neurobiological framework that could explain both the non-addictive nature of CH and their potential to treat substance dependence. Specifically, the authors develop and defend a hypothesis in which activation of 5-HT2C receptors—particularly on medium spiny GABAergic neurons in the nucleus accumbens (NAc) shell—modulates intrinsic neuronal excitability (via inhibition of Kv1.x potassium channels), thereby suppressing mesolimbic dopamine signalling that underlies addictive behaviours.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Study Details

  • Study Type
    meta
  • Journal
  • Topic
  • APA Citation

    Canal, C. E., & Murnane, K. S. (2017). The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens. Journal of Psychopharmacology, 31(1), 127-143. https://doi.org/10.1177/0269881116677104

References (21)

Papers cited by this study that are also in Blossom

Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study

Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)

Classic hallucinogens in the treatment of addictions

Bogenschutz, M. P., Johnson, M. W. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2016)

Flashback: psychiatric experimentation with LSD in historical perspective

Dyck, E. · Canadian Journal of Psychiatry (2005)

90 cited
Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior

Gonza ´lez-Maeso, J., Weisstaub, N. V., Zhou, M. et al. · Neuron (2007)

818 cited
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects

Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)

Recent advances in the neuropsychopharmacology of serotonergic hallucinogens

Halberstadt, A. L. · Behavioural Brain Research (2014)

Animal models of serotonergic psychedelics

Hanks, J. B., González-Maeso, J. · ACS Chemical Neuroscience (2012)

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)

Show all 21 references
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials

Krebs, T. S., Johansen, P. Ø. · Journal of Psychopharmacology (2012)

A clinical study of LSD treatment in alcoholism

Ludwig, A., Levine, J., Stark, L. et al. · American Journal of Psychiatry (1969)

158 cited
Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness

Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)

Psychedelics and the human receptorome

Ray, T. S. · PLOS ONE (2010)

265 cited
118 cited
Prediction of psilocybin response in healthy volunteers

Studerus, E., Gamma, A., Kometer, M. et al. · PLOS ONE (2012)

Lysergide Treatment of Schizophrenic and Nonschizophrenic Alcoholics; A Controlled Evaluation

Tomsovic, M., Edwards, R. V. · Journal of Studies on Alcohol and Drugs (1970)

55 cited
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action

Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)

Cited By (8)

Papers in Blossom that reference this study

Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics

Jaster, A. M., González-Maeso, J. · Molecular Psychiatry (2023)

The association between naturalistic use of psychedelics and co-occurring substance use disorders

Rabinowitz, J., Lev-Ran, S., Gross, R. · Frontiers in Psychiatry (2023)

Toward a positive psychology of psychoactive drug use

Arnaud, K. O. S. · Drugs Education Prevention and Policy (2021)

A narrative synthesis of research with 5-MeO-DMT

Ermakova, A. O., Dunbar, F., Rucker, J. et al. · Journal of Psychopharmacology (2021)

Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics

Schindler, E. A. D., Wallace, R. M., Sloshower, J. A. et al. · Frontiers in Pharmacology (2018)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.

The serotonin 5-HT2C receptor and the... — Research Summary & Context | Blossom